| Revisiting the Cholinergic Hypothesis in Alzheimer's Disease: Emerging Evidence from Translational and Clinical Research |
20 |
| Development of Azeliragon, an Oral Small Molecule Antagonist of the Receptor for Advanced Glycation Endproducts, for the Potential Slowing of Loss of Cognition in Mild Alzheimer's Disease |
16 |
| AADvac an Active Immunotherapy for Alzheimer's Disease and Non Alzheimer Tauopathies: An Overview of Preclinical and Clinical Development |
14 |
| Female Sex and Alzheimer's Risk: The Menopause Connection |
14 |
| Anti-Tau Trials for Alzheimer's Disease: A Report from the EU/US/CTAD Task Force |
13 |
| Increased Functional Connectivity After Listening to Favored Music in Adults With Alzheimer Dementia |
12 |
| Plasma Biomarkers of AD Emerging as Essential Tools for Drug Development: An EU/US CTAD Task Force Report |
12 |
| Bifidobacterium Breve A1 Supplementation Improved Cognitive Decline in Older Adults with Mild Cognitive Impairment: An Open-Label, Single-Arm Study |
11 |
| Combination Therapy for Alzheimer's Disease: Perspectives of the EU/US CTAD Task Force |
11 |
| Polygenic Risk Score Analysis of Alzheimer's Disease in Cases without APOE4 or APOE2 Alleles |
9 |
| Pimavanserin: Potential Treatment For Dementia-Related Psychosis |
9 |
| Plasma A beta 42/40 Ratio Detects Early Stages of Alzheimer's Disease and Correlates with CSF and Neuroimaging Biomarkers in the AB255 Study |
8 |
| Dietary Fat Intake and Cognitive Function among Older Populations: A Systematic Review and Meta-Analysis |
7 |
| Factors Associated with Alzheimer's Disease: An Overview of Reviews |
7 |
| Cognitive Frailty and Incidence of Dementia in Older Persons |
6 |
| The Relationship of Omega 3 Polyunsaturated Fatty Acids in Red Blood Cell Membranes with Cognitive Function and Brain Structure: A Review Focussed on Alzheimer's Disease |
6 |
| Pimavanserin in Alzheimer's Disease Psychosis: Efficacy in Patients with More Pronounced Psychotic Symptoms |
6 |
| Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer's Disease using Cerebrospinal Fluid Biomarkers in the AIBL Study |
6 |
| Biological and Cognitive Markers of Presenilin1 E280A Autosomal Dominant Alzheimer's Disease: A Comprehensive Review of the Colombian Kindred |
6 |
| What Have We Learned from Expedition III and EPOCH Trials? Perspective of the CTAD Task Force |
5 |
| Effects of Omega-3 Fatty Acids on Resting Cerebral Perfusion in Patients with Mild Cognitive Impairment: A Randomized Controlled Trial |
4 |
| Treatable Vascular Risk and Cognitive Performance in Persons Aged 35 Years or Older: Longitudinal Study of Six Years |
4 |
| Clinical Application of APOE in Alzheimer's Prevention: A Precision Medicine Approach |
4 |
| Assessment of Instrumental Activities of Daily Living in Older Adults with Subjective Cognitive Decline Using the Virtual Reality Functional Capacity Assessment Tool (VRFCAT) |
4 |
| Mediterranean-Dash Intervention for Neurodegenerative Delay (MIND) Diet Slows Cognitive Decline After Stroke |
4 |
| Treatment Effects of Vortioxetine on Cognitive Functions in Mild Alzheimer's Disease Patients with Depressive Symptoms: A 12 Month, Open-Label, Observational Study |
4 |
| Identifying Better Outcome Measures to Improve Treatment of Agitation in Dementia: A Report from the EU/US/CTAD Task Force |
4 |
| Strong Relationship between Malnutrition and Cognitive Frailty in the Singapore Longitudinal Ageing Studies (SLAS-1 and SLAS-2) |
3 |
| A Literature Review of Methodologies Used in Randomized Clinical Trials of Agitation in Alzheimer's Disease |
3 |
| Alzheimer's Disease Composite Score: a Post-Hoc Analysis Using Data from the LipiDiDiet Trial in Prodromal Alzheimer's Disease |
3 |
| Auraptene in the Peels of Citrus Kawachiensis (Kawachibankan) Contributes to the Preservation of Cognitive Function: A Randomized, Placebo-Controlled, Double-Blind Study in Healthy Volunteers |
3 |
| Psychometric Evaluation of the Neuropsychological Test Battery in Individuals with Normal Cognition, Mild Cognitive Impairment, or Mild to Moderate Alzheimer's Disease: Results from a Longitudinal Study |
3 |
| Shift in Hospitalizations for Alzheimer's Disease to Related Dementias in France between 2007 and 2017 |
3 |
| Diet as a Risk Factor for Cognitive Decline in African Americans and Caucasians with a Parental History of Alzheimer's Disease: A Cross-Sectional Pilot Study Dietary Patterns |
3 |
| Trajectory of the MAPT-PACC-Preclinical Alzheimer Cognitive Composite in the Placebo Group of a Randomized Control Trial: Results from the MAPT Study: Lessons for Further Trials |
3 |
| Associations of Long-Term Tea Consumption with Depressive and Anxiety Symptoms in Community-Living Elderly: Findings from the Diet and Healthy Aging Study |
3 |
| Delayed-Start Analyses in the Phase 3 Solanezumab EXPEDITION3 Study in Mild Alzheimer's Disease |
3 |
| Assessment of Clinical Meaningfulness of Endpoints in the Generation Program by the Insights to Model Alzheimer's Progression in Real Life (iMAP) Study |
2 |
| Analysis of the Relationship of Cognitive Impairment and Functional Impairment in Mild Alzheimer's Disease in EXPEDITION 3 |
2 |
| Correlation of CSF- and MRI-Biomarkers and Progression of Cognitive Decline in an Open Label MCI Trial |
2 |
| An Action Plan to Face the Challenge of Dementia: INTERNATIONAL STATEMENT ON DEMENTIA from IAP for Health |
2 |
| Is a Large-Scale Screening for Alzheimer's Disease Possible? Yes, in a Few Years |
2 |
| Randomized, Placebo Controlled Trial of NPT A Phage-Derived, Amyloid-Targeted Treatment for Alzheimer's Disease |
2 |
| Prospective Evaluation of Cognitive Health and Related Factors in Elderly at Risk for Developing Alzheimer's Dementia: A Longitudinal Cohort Study |
2 |
| Machine Learning Algorithm Helps Identify Non-Diagnosed Prodromal Alzheimer's Disease Patients in the General Population |
2 |
| Adherence to the Mediterranean Diet Is not Related to Beta-Amyloid Deposition: Data from the Women's Healthy Ageing Project |
2 |
| Biomarker and Clinical Trial Design Support for Disease-Modifying Therapies: Report of a Survey of the EU/US: Alzheimer's Disease Task Force |
1 |
| Advancing Alzheimer's Disease Treatment: Lessons from CTAD 2018 |
1 |
| Utilization of Observational Data as a Proxy Cohort for Comparison Purposes with Open-Label Study Results: An Example from Alzheimer's Disease |
1 |
| Geographic Clusters of Alzheimer's Disease Mortality Rates in the USA: 2008-2012 |
1 |
